Swiss Roche to create autonomous AI research labs
One of the world’s largest pharmaceutical groups, Swiss Roche, has begun building autonomous AI-based labs to accelerate research and development. As noted at a meeting with investors, the Executive Vice President of research Roche Aviv Regev, the company is committed to “AI independence”.
One of the world’s largest pharmaceutical groups, Swiss Roche, has begun building autonomous AI-based labs to accelerate research and development.
As noted at a meeting with investors, the Executive Vice President of research Roche Aviv Regev, the company is committed to “AI independence”. The creation of such laboratories will save 2 billion Swiss francs (€2.1 billion), which will be used to increase the productivity of the company's operations as early as 2026.
Roche notes growing clinical trial success rates, from 65 percent in 2025 to about 80 percent in 2026. Since the fourth quarter of 2025, 40% of decisions to develop new drugs have already been made with AI in mind.
Ekaterina Naumova
